94E Stock Chart & Stats
€4.62
€0.16(3.46%)
At close: 4:00 PM EDT
€4.62
€0.16(3.46%)
Day’s Range― - ―
52-Week Range€1.26 - €6.00
Previous CloseN/A
Volume151.00
Average Volume (3M)0.00
Market Cap
€480.19M
Enterprise Value€543.01
Total Cash (Recent Filing)€205.13M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Nov 18, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding95,829,140
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.86
Price to Sales (P/S)0.00
P/FCF Ratio-7.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€18.20Price Target Upside293.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ExecutionCompleting and exceeding enrollment targets in two Phase 2 tibulizumab trials demonstrates durable operational execution and trial management capabilities. This reduces clinical enrollment risk, supports timely topline readouts, and strengthens the program's chance to progress to later-stage studies or partner interest over the next 2–6 months.
Funding RunwayA multi-year cash runway through at least end-2028 provides structural financial flexibility to fund Phase 2 activities and associated R&D without immediate dilution. This extends the company’s ability to reach key clinical readouts and regulatory interactions, lowering short-term financing risk and enabling strategic partnership discussions.
Debt-Free Balance SheetA debt-free capital structure and materially higher equity/assets reduce interest burden and financial distress risk. This strengthens strategic optionality—funding R&D, pursuing collaborations, or managing setbacks—since the company can prioritize operational spending without near-term fixed debt obligations.
Bears Say
No RevenueLack of product revenue is a persistent structural constraint: the company remains pre-commercial and must rely on financing to fund operations until clinical success and commercialization. This makes long-term sustainability contingent on trial outcomes and external capital, leaving operating leverage and profitability uncertain.
Worsening Cash BurnSteadily worsening operating cash flow and deeply negative free cash flow indicate structural cash consumption tied to advancing multiple clinical programs. Even with current runway, ongoing high burn raises the probability of future equity raises or partnerships, which can dilute shareholders and influence strategic choices over the medium term.
Expanding Losses & Negative ReturnsRising net losses and negative returns on equity reflect that capital invested is not generating profit and that operating scale is not yet achieved. Persisting losses can erode equity over time if unchecked, limiting flexibility and potentially pressuring governance or prompting strategic trade-offs if clinical advances stall.
Zura Bio News
94E FAQ
What was Zura Bio’s price range in the past 12 months?
Zura Bio lowest stock price was €1.26 and its highest was €6.00 in the past 12 months.
What is Zura Bio’s market cap?
Zura Bio’s market cap is €480.19M.
When is Zura Bio’s upcoming earnings report date?
Zura Bio’s upcoming earnings report date is Nov 18, 2026 which is in 96 days.
How were Zura Bio’s earnings last quarter?
Zura Bio released its earnings results on Aug 11, 2026. The company reported -€0.182 earnings per share for the quarter, missing the consensus estimate of -€0.166 by -€0.016.
Is Zura Bio overvalued?
According to Wall Street analysts Zura Bio’s price is currently Undervalued.
Does Zura Bio pay dividends?
Zura Bio does not currently pay dividends.
What is Zura Bio’s EPS estimate?
Zura Bio’s EPS estimate is -0.18.
How many shares outstanding does Zura Bio have?
Zura Bio has 95,829,140 shares outstanding.
What happened to Zura Bio’s price movement after its last earnings report?
Zura Bio reported an EPS of -€0.182 in its last earnings report, missing expectations of -€0.166. Following the earnings report the stock price went down -6.408%.
Which hedge fund is a major shareholder of Zura Bio?
Currently, no hedge funds are holding shares in DE:94E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zura Bio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€18.20 (293.95% Upside)
€18.20 (293.95% Upside)
Blogger Sentiment
Bullish
DE:94E Sentiment 100%
Sector Average 62%
Sector Average 62%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
211.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.23%
Trailing 12-Months
Company Description
Zura Bio
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
94E Stock 12 Month Forecast
Average Price Target
€18.20
▲(293.95% Upside)